Dyumn Dwivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dyumn Dwivedi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- B. V. Uday Kumar
School of Agricultural Biotechnology, Punjab Agricultural University, Ludhiana, India
1 shared publication - Chandralekha Nair
Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano Statale, Milano, Italy 201223, Italy
1 shared publication - Dewang Singh
Department of Human Genetics and Molecular Medicine, Central University of Punjab, Punjab, India, 151401, India
1 shared publication - Gopukumar Sivakumar Thangam
Nanobioinformatics Unit, Department of General Surgery, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha Medical College and Hospital, Saveetha University, Chennai, India
1 shared publication - K. Gowri
Department of Pharmacology, SRM College of Pharmacy, SRM Institute Of Science and Technology, Kattankulathur, Tamilnadu, India, 603203, India
1 shared publication - Karpakavalli Meenakshi Sundaram
Department of Pharmaceutical Chemistry, Karpagam College of Pharmacy, Coimbatore, Tamil Nadu, India 641032, India
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by MDPI AG in Preprints.org
Repurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and Senescence
Alzheimer's disease (AD), the predominant dementia etiology, imposes a $1.5 trillion global burden in 2025, exacerbated by inexorable failures in amyloid-tau-centric monotherapies amid <1% trial success rates. This review synthesizes cross-disciplinary pathobiology underpinning oncology drug repurposing for AD, leveraging inverse epidemiological antagonism and convergent hallmarks: aberrant neuronal cell-cycle re-entry (CDK5/p25, ERK-MAPK), proteostasis overload (HSP90-UPS-autophagy nexus), mTORC1 hyperactivation impairing lysosomal flux, kynurenine pathway (IDO1/TDO)-driven immunometabolic decoupling, PARP1-mediated NAD+ parthanatos, maladaptive neuroinflammation (PD-1/PD-L1 checkpoints, TAM-microglial skewing), and senescence-associated secretory phenotype (SASP)-amplified gliosis. Computational nomination pipelines—transcriptomic signature reversal (CMap/LINCS), network proximity in multi-omic knowledge graphs, and ligand-based docking—prioritize pleiotropic oncology agents: c-Abl/Src TKIs (nilotinib, bosutinib) enhancing autophagic Aβ/tau clearance; multikinase modulators (masitinib) resolving mast cell-microglial dyshomeostasis; rapalogs restoring proteostasis; IDO1 antagonists normalizing astrocytic lactate shuttling; PARPi mitigating genomic instability; HDACi reinstating synaptic epigenomes; and senolytics (dasatinib+quercetin) purging senescent glia. Phase I/II trials evince biomarker modulation (↓CSF p-tau, amyloid-PET; ↑autophagic flux) with geriatric-adapted dosing, yet underscore translational hurdles: BBB penetration, off-target liabilities, and polypharmacy in APOE ε4-enriched cohorts. A precision roadmap advocates orthogonal combinations (e.g., TKI+IDO1i), delivery-first PBPK modeling, and biomarker-anchored adaptive platforms to recalibrate AD's networked trajectory toward disease-modifying efficacy.
- 23 September 2025
- Published by MDPI AG in Preprints.org
Open AccessRepurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and Senescence
Alzheimer's disease (AD), the predominant dementia etiology, imposes a $1.5 trillion global burden in 2025, exacerbated by inexorable failures in amyloid-tau-centric monotherapies amid <1% trial success rates. This review synthesizes cross-disciplinary pathobiology underpinning oncology drug repurposing for AD, leveraging inverse epidemiological antagonism and convergent hallmarks: aberrant neuronal cell-cycle re-entry (CDK5/p25, ERK-MAPK), proteostasis overload (HSP90-UPS-autophagy nexus), mTORC1 hyperactivation impairing lysosomal flux, kynurenine pathway (IDO1/TDO)-driven immunometabolic decoupling, PARP1-mediated NAD+ parthanatos, maladaptive neuroinflammation (PD-1/PD-L1 checkpoints, TAM-microglial skewing), and senescence-associated secretory phenotype (SASP)-amplified gliosis. Computational nomination pipelines—transcriptomic signature reversal (CMap/LINCS), network proximity in multi-omic knowledge graphs, and ligand-based docking—prioritize pleiotropic oncology agents: c-Abl/Src TKIs (nilotinib, bosutinib) enhancing autophagic Aβ/tau clearance; multikinase modulators (masitinib) resolving mast cell-microglial dyshomeostasis; rapalogs restoring proteostasis; IDO1 antagonists normalizing astrocytic lactate shuttling; PARPi mitigating genomic instability; HDACi reinstating synaptic epigenomes; and senolytics (dasatinib+quercetin) purging senescent glia. Phase I/II trials evince biomarker modulation (↓CSF p-tau, amyloid-PET; ↑autophagic flux) with geriatric-adapted dosing, yet underscore translational hurdles: BBB penetration, off-target liabilities, and polypharmacy in APOE ε4-enriched cohorts. A precision roadmap advocates orthogonal combinations (e.g., TKI+IDO1i), delivery-first PBPK modeling, and biomarker-anchored adaptive platforms to recalibrate AD's networked trajectory toward disease-modifying efficacy.
- Open Access
- 24 June 2025
- Published by MDPI AG in Preprints.org
Advancements in CRISPR-Mediated Multiplex Genome Editing: Transforming Plant Breeding for Crop Improvement and Polygenic Trait Engineering
The advent of CRISPR/Cas systems has revolutionized plant genome engineering, transitioning from traditional single-gene edits to sophisticated multiplex genome editing strategies capable of simultaneously targeting multiple loci. This review provides an in-depth examination of CRISPR-mediated multiplexing technologies in plants, emphasizing their molecular mechanisms, delivery systems, and transformative applications in crop improvement. We delineate the evolution of CRISPR systems from early programmable nucleases to diverse Class 2 effectors, including Cas9, Cas12, Cas13, and emerging ultra-compact variants like CasΦ and Cas14. We detail polycistronic gRNA expression platforms—such as tRNA-sgRNA arrays, ribozymes, and Csy4-mediated cleavage—that enable efficient multi-target editing within compact vectors. Furthermore, we explore advanced delivery modalities including Agrobacterium, biolistics, protoplast transfection, and viral vectors, optimized for recalcitrant plant systems. Applications span yield enhancement, disease resistance, abiotic stress tolerance, nutritional fortification, and de novo domestication. Critical challenges including off-target mutagenesis, mosaicism, chromosomal rearrangements, and regulatory constraints are addressed. Finally, we highlight AI-driven sgRNA design, multi-omics integration, and CRISPR libraries as pivotal tools to rationalize and scale multiplex editing. This synthesis underscores multiplex CRISPR as a cornerstone of next-generation plant breeding, with the potential to redefine global agriculture through precision trait stacking and rapid varietal development.
- 24 June 2025
- Published by MDPI AG in Preprints.org
Open AccessAdvancements in CRISPR-Mediated Multiplex Genome Editing: Transforming Plant Breeding for Crop Improvement and Polygenic Trait Engineering
The advent of CRISPR/Cas systems has revolutionized plant genome engineering, transitioning from traditional single-gene edits to sophisticated multiplex genome editing strategies capable of simultaneously targeting multiple loci. This review provides an in-depth examination of CRISPR-mediated multiplexing technologies in plants, emphasizing their molecular mechanisms, delivery systems, and transformative applications in crop improvement. We delineate the evolution of CRISPR systems from early programmable nucleases to diverse Class 2 effectors, including Cas9, Cas12, Cas13, and emerging ultra-compact variants like CasΦ and Cas14. We detail polycistronic gRNA expression platforms—such as tRNA-sgRNA arrays, ribozymes, and Csy4-mediated cleavage—that enable efficient multi-target editing within compact vectors. Furthermore, we explore advanced delivery modalities including Agrobacterium, biolistics, protoplast transfection, and viral vectors, optimized for recalcitrant plant systems. Applications span yield enhancement, disease resistance, abiotic stress tolerance, nutritional fortification, and de novo domestication. Critical challenges including off-target mutagenesis, mosaicism, chromosomal rearrangements, and regulatory constraints are addressed. Finally, we highlight AI-driven sgRNA design, multi-omics integration, and CRISPR libraries as pivotal tools to rationalize and scale multiplex editing. This synthesis underscores multiplex CRISPR as a cornerstone of next-generation plant breeding, with the potential to redefine global agriculture through precision trait stacking and rapid varietal development.